Cable Forum - View Single Post

**Hugh** · 13-06-2019, 11:50

Quote:

Originally Posted by nomadking

Quote:

First of all let's head north - to the border between Norway and Sweden.
Sweden is in the EU, Norway isn't.

...

And the average time from when a lorry arrives to when it leaves the border? About 20 minutes. That includes roughly 10 minutes waiting time, three to six minutes of handling time, and the time spent coming off the road to complete the customs process.

Link
Still absolutely nowhere near 3 months.

Remember the delays work in both directions, and that will include returning lorries. Are the EU going to be happy with adding 2 days until they get their lorries back after delivering to the UK?

So much for the "single market".

You accidently missed a bit from the article about Norway and Sweden...

Quote:

Being in the single market means Norway respects the EU's four freedoms - the freedom of movement of goods, services, capital and people.

And you are, (accidently, I am sure) in your linked example about Turkey, conflating queuing times with pharmaceutical Supply Change Management - pharma multi-country SCM isn't just about queuing, it's about potential impact of regulatory changes and the requirements for some components in the Supply Chain to have to get licences to Contract Manufactures (which they didn't need to before).

This article is from two legal experts in regulatory issues on EU Life Sciences Law

https://www.pharmalogisticsiq.com/lo...es-post-brexit

Quote:

In terms of broader supply chain issues, the supply chain for many medicines involves moving products or ingredients across the UK-EU border at one or more stages in the manufacturing process. Any increase in tariffs or non-tariff barriers, such as additional paperwork or delays, could disrupt the supply chain and potentially lead to shortages (even if the product meets all regulatory requirements). This risk is particularly acute for the pharmaceutical sector given the complex and time-critical supply chains and the need for many medicines to be kept in cold storage during transport and storage.

Shortages of supply are most likely to occur in relation to those products with a centralised marketing authorisation held by a UK company or authorisation based on mutual recognition involving a UK entity or authorisation. Although this may represent a substantial number of products, in practice, the immediate shortage is more likely to occur in relation to those products with a short shelf life or cold chain requirements.

Given the regulatory procedure that governs marketing authorisation and release of medicinal products in the EU and the potential impacts on the supply chain, shortages of supply of products in the UK in the event of a hard Brexit cannot be excluded. Medicinal products for which marketing authorisation is held in one of the 27 EU Member States may not be so greatly impacted. This is because, unlike products for which a marketing authorisation is currently held in the UK, these will continue to be freely supplied in the EU after Brexit. The potential exception to this would be in relation to products manufactured in the UK for the EU market.

Equally, from a UK perspective, while the UK is likely to set up a process for issuing national authorisations based on the existing EU authorisation and recognise EU release, there may be practical difficulties in moving products across the border from the EU into the UK...

...Where the issue is transferring manufacturing steps taking place in the UK, such as batch release, stockpiling may not be sufficient to tide companies over until batch release has been moved to an EU site as this is not a quick process. Stockpiling is also not without its challenges as the warehousing facilities used must meet certain regulatory standards. This creates potential cash flow issues given that companies often have to pay suppliers before they have received payment for the product from customers.